Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
Published . Updated .
The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.
Directly affected
- PPLI People
Named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.
Source: MarketWatch
Acadia Healthcare (ACHC) since this story, compared with the market
Since the first closing price after “Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.,” Acadia Healthcare (ACHC) is +12.10%. The S&P 500 fund (SPY) is +0.33% over the same days, a +11.77% difference versus the market.
Official trades in Acadia Healthcare (ACHC) around 30 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 1 days before publication, inside 30 days. The filing is listed beside the story “Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects..”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 19 days before publication, inside 30 days. The filing is listed beside the story “Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects..”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 58 days before publication, inside 60 days. The filing is listed beside the story “Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects..”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Acadia Healthcare (ACHC)
Companies tied to this story
- ACHC Acadia Healthcare
Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence in the 30 Sep 2026 story “Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects..” Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence in the 30 Sep 2026 story “Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects..” Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
For “Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
For “Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
For “Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
In “Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.,” GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Acadia Healthcare (ACHC)
On 30 Sep 2026, “Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.” is the story that connects Acadia Healthcare (ACHC) to this story.
What ties Acadia Healthcare (ACHC) to the headline is this: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Ascendis Pharma A/S (ASND) is here too. Its reason reads: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Price levels for Acadia Healthcare (ACHC)
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.
A simple score for Acadia Healthcare (ACHC)
46 out of 100
“Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.